Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer

Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain

IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )

Bladder cancer: Latest advances in targeted therapies and precision medicine...

Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and...

Bladder cancer: Latest advances in targeted therapies and precision medicine from ESMO 2019 ( Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr Michiel Van der Heijden )

Latest developments in metastatic prostate cancer from ESMO 2019

Prof Nick James and Prof Nicholas Mottet

Latest developments in metastatic prostate cancer from ESMO 2019 ( Prof Nick James and Prof Nicholas Mottet )

PARP inhibitor olaparib slows progression of advanced prostate cancer

Prof Maha Hussain - Northwestern University Feinberg School of Medicine...

PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )

Role of biomarkers, targeted therapy and tumour mutations in the landscape of...

Prof Petros Grivas and Dr Michiel Van der Heijden

Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer ( Prof Petros Grivas and Dr Michiel Van der Heijden )

Comment: PARP inhibitors for advanced prostate cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain

Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )

Comment: Immunotherapy plus chemotherapy in bladder cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain

Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )

Atezolizumab added to chemotherapy prolongs progression free survival in...

Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain

Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

Implementing national cancer control plans

Dr Eduardo Cazap and Dr Lisa Stevens

Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )

Comment: Enfortumab vedotin is an effective therapy and important development...

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )

More from ecancer